LaSalle Street Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

LaSalle Street Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,445	Closed	-$261K	–	106
2018 Q2	$261K	Sell	3,445 -1,625	-32%	-$102K	0.26%	95
2018 Q1	$267K	Sell	5,070 -226	-4%	-$13.1K	0.21%	98
2017 Q4	$283K	Buy	5,296 +720	+16%	+$40.1K	0.2%	96
2017 Q3	$273K	Buy	+4,576	New	+$277K	0.2%	95
2016 Q4	–	Sell	-4,278	Closed	-$299K	–	99
2016 Q3	$299K	Sell	4,278 -3,568	-45%	-$198K	0.28%	68
2016 Q2	$304K	Buy	+7,846	New	+$327K	0.29%	67

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

LaSalle Street Capital Management's EGRX Position: Q3 2018 in Review

LaSalle Street Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2018, closing a stake of 3,445 shares — an estimated $261K sold.

LaSalle Street Capital Management first reported a position in EGRX in Q2 2016 and held it in 6 quarters. The position peaked at $304K in Q2 2016. 189 funds tracked by Wall St. Rank hold EGRX as of Q3 2018.

LaSalle Street Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
LaSalle Street Capital Management sold 3,445 Eagle Pharmaceuticals, Inc. shares in Q3 2018, an estimated $261K.
LaSalle Street Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 6 quarters.
LaSalle Street Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $304K in Q2 2016.
189 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2018.

Based on LaSalle Street Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.